Incretin Microdosing for Cardiometabolic Health in People With HIV

NCT07325500 on ClinicalTrials.gov · last registry update 2026-02-18

A small phase 2 — 30 participants, against a typical 110. Due to report 31 May 2028, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Percent weight regain from weeks 12-60 (microdosing period). Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: The University of Texas Health Science Center, Houston
Sponsor type: Other
Enrollment: 30
Started: 2026-02-12
Primary completion: 2028-05-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent weight regain from weeks 12-60 (microdosing period)

Conditions studied

Weight Gain

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.